Ozempic Face and Butt: Skin and Muscle Side Effects
GLP-1 Weight Loss and Body Composition
39%
Of total weight lost on semaglutide 2.4 mg came from lean body mass in the STEP 1 trial, raising questions about what rapid weight loss costs beyond fat.
Bikou et al., Expert Opinion on Pharmacotherapy, 2024
Bikou et al., Expert Opinion on Pharmacotherapy, 2024
View as imageThe terms "ozempic face" and "ozempic butt" entered mainstream vocabulary before the medical literature caught up with them. Coined by dermatologists and plastic surgeons observing patients on semaglutide and tirzepatide, these colloquial labels describe the visible consequences of rapid weight loss: facial hollowing, skin sagging, and a deflated appearance in areas where subcutaneous fat once provided structure.[1] These are not side effects of the drugs themselves. They are side effects of losing weight quickly, and they reflect a broader question about what GLP-1 weight loss does to body composition beyond the number on a scale.
Key Takeaways
- In the STEP 1 trial, semaglutide 2.4 mg caused 5.3 kg of lean body mass loss over 68 weeks, compared to 1.4 kg with placebo (Bikou et al., Expert Opinion on Pharmacotherapy, 2024)
- A systematic review of six semaglutide trials found lean mass reductions ranging from nearly 0% to 40% of total weight lost, with variability depending on the study population and measurement method (Bikou et al., 2024)
- Over 25% of total weight lost from both GLP-1 pharmacotherapy and bariatric surgery comes from fat-free mass, with the myostatin-activin-follistatin system identified as a key regulator (Stefanakis et al., 2024)
- Facial plastic surgeons reported increased consultation volume for patients on semaglutide seeking treatment for temporal hollowing, nasolabial fold deepening, and jowling (Humphrey et al., Facial Plastic Surgery, 2023)
- Physical activity combined with GLP-1 drugs preserves muscle mass and enhances metabolic outcomes compared to medication alone (Ablah et al., 2025)
- Tirzepatide's body composition effects vary across trials, with the fat-to-lean mass loss ratio requiring clinical attention in each patient (Rochira et al., 2024)
What Is Ozempic Face?
"Ozempic face" describes the facial appearance changes that occur when rapid weight loss depletes the subcutaneous fat pads that give the face its youthful volume. The buccal fat pads, malar fat pads, and periorbital fat all diminish, producing temporal hollowing, deepened nasolabial folds, prominent cheekbones over gaunt cheeks, visible platysmal bands in the neck, and loose skin along the jawline.[1]
Humphrey and colleagues published one of the first clinical assessments of this phenomenon in Facial Plastic Surgery in 2023. They noted that semaglutide-related facial changes created a new patient population for plastic surgeons: people who were happy with their weight loss but distressed by how much older they looked.[1]
The effect is not unique to GLP-1 drugs. Any rapid weight loss, whether from bariatric surgery, severe caloric restriction, or illness, can produce similar facial changes. The distinguishing factor with GLP-1 medications is the scale: semaglutide 2.4 mg produces average weight losses of 15-17% of body weight over 68 weeks, and tirzepatide can exceed 20%. Losing that much weight in slightly over a year does not give facial skin time to remodel and contract around the reduced volume.
Two mechanisms drive the visible aging. First, rapid fat loss outpaces the skin's ability to shrink. Collagen and elastin fibers that previously stretched around a larger fat compartment now drape loosely, producing sagging and wrinkling. Second, the loss of facial fat pads themselves eliminates the structural scaffolding that supports the overlying skin. The face effectively loses its internal framework.
What Is Ozempic Butt?
"Ozempic butt" refers to the flattened, saggy appearance of the buttocks after significant weight loss. The gluteal region depends on both fat and muscle for its shape, and rapid weight loss can reduce both simultaneously.
The gluteus maximus is one of the largest muscles in the body, but it sits beneath a substantial layer of subcutaneous fat. When that fat layer thins rapidly, the remaining skin sags. If muscle mass also declines (which it does in many GLP-1 users, as discussed below), the structural deficit compounds.
This effect extends beyond the buttocks. Similar changes appear in the breasts, upper arms, inner thighs, and abdomen. Anywhere the body stored significant subcutaneous fat, rapid depletion leaves excess skin and reduced tissue volume. The term "ozempic body" has emerged as a catch-all for these distributed changes, though it lacks any clinical definition.
The speed of fat loss is the critical variable. Gradual weight loss (0.5 to 1 kg per week) allows some tissue remodeling and gives remaining muscle more time to adapt to the changing load demands. The aggressive weight trajectories seen with higher-dose semaglutide and tirzepatide compress this timeline, producing more dramatic visual changes in a shorter window.
How Much Lean Mass Do GLP-1 Drugs Actually Cost?
This question generated significant debate in the medical literature between 2023 and 2025. Bikou and colleagues published a systematic review in Expert Opinion on Pharmacotherapy in 2024, analyzing six semaglutide clinical trials with 1,541 overweight or obese participants.[2]
Their findings:
- Total weight reduction was primarily from fat mass in all trials
- Lean mass reductions ranged from nearly 0% to 40% of total weight lost
- In the STEP 1 trial specifically, lean body mass decreased by 5.26 kg with semaglutide 2.4 mg versus 1.37 kg with placebo over 68 weeks
- Despite absolute lean mass loss, the proportion of lean mass relative to total body weight increased by about 3 percentage points
That last finding is critical context. A person who weighs 100 kg and is 60% lean mass loses 15 kg total, with 6 kg from lean mass. Their new lean-to-total ratio is actually higher (63.5% vs 60%) even though they lost absolute lean tissue. The body is proportionally leaner, but the absolute muscle loss may still affect function.
Stefanakis and colleagues broadened this analysis in 2024, examining fat-free mass loss across both GLP-1 pharmacotherapy and bariatric surgery. They found over 25% of total weight lost from both approaches comes from fat-free mass, and identified the myostatin-activin-follistatin system as a crucial regulator of lean mass preservation during negative energy balance.[3]
The distinction between how much muscle is lost versus total lean mass matters. "Lean mass" includes not just skeletal muscle but also organ tissue, water, glycogen stores, and connective tissue. A 2025 mouse study found that much of semaglutide-induced lean mass loss came from liver shrinkage (the liver reduced by nearly half) rather than skeletal muscle. Muscles showed decreased strength even when their size was relatively preserved, suggesting functional changes beyond simple atrophy.
Who Loses the Most Lean Mass?
Not everyone on GLP-1 drugs experiences the same degree of muscle or skin effects. Several factors predict worse outcomes:
Age. Older adults lose proportionally more lean mass during weight loss. They also have less skin elasticity to accommodate volume changes, making facial and body skin laxity more pronounced. The sarcopenia risk in older GLP-1 users is a separate and serious concern.
Starting body composition. People with lower baseline muscle mass lose a higher percentage of their remaining lean tissue. Someone who is already sarcopenic at baseline faces compounding deficits. The bone density consequences of this lean mass loss add another layer of risk.
Sex. Women tend to lose more lean mass on semaglutide than men, a finding consistent across multiple trials. A 2025 ENDO conference presentation reported that being female was independently associated with greater muscle loss.[5]
Protein intake. Insufficient protein accelerates lean mass loss. The body needs amino acids to maintain muscle during caloric deficit, and GLP-1 drugs suppress appetite enough that many patients struggle to eat adequate protein. This is addressable, and it connects to the broader question of how much protein GLP-1 users actually need.
Physical inactivity. Ablah and colleagues reported in 2025 that combining physical activity with GLP-1 drugs preserved muscle mass, enhanced metabolic improvements, and improved cardiovascular fitness compared to medication alone.[5] Patients who take the medication without any resistance training lose more lean tissue.
Tirzepatide vs. Semaglutide: Does the Drug Matter?
Rochira and colleagues examined tirzepatide's body composition effects in a 2024 review. They found that tirzepatide consistently reduces fat mass in people with overweight or obesity, but the ratio of fat to lean mass loss varies between trials and needs individualized clinical monitoring.[4]
Some early data suggested tirzepatide may preserve lean mass better than semaglutide, possibly because the GIP receptor agonism provides additional metabolic effects. The SURMOUNT trials reported that tirzepatide-treated participants lost a higher proportion of fat relative to lean tissue than is typically seen with semaglutide. But head-to-head body composition studies with standardized measurement methods (DXA) remain limited.
The practical implication: whether visible "ozempic face" or body laxity develops depends less on which specific GLP-1 drug is used and more on how much weight is lost, how fast it comes off, and what is done to preserve lean tissue during the process. For a deeper comparison, see does semaglutide change your body composition.
What the Skin Research Shows
The dermatologic implications of rapid GLP-1-mediated weight loss are an emerging area of study. When subcutaneous fat diminishes quickly, the overlying skin loses structural support. Collagen and elastin fibers, which provide tensile strength and elasticity, cannot remodel fast enough to match the pace of volume loss.
Several mechanisms contribute:
- Collagen degradation. Rapid weight loss is associated with increased matrix metalloproteinase activity, enzymes that break down collagen. The skin simultaneously loses the mechanical stimulation from underlying fat that helps maintain collagen production.
- Elastin damage. Unlike collagen, elastin has almost no turnover in adult skin. Once stretched beyond its recoil capacity, it does not return to its original length. This is why skin laxity from rapid weight loss is often permanent without surgical intervention.
- Reduced dermal blood flow. Loss of subcutaneous fat decreases the vascular supply to overlying skin, potentially impairing its ability to maintain and repair itself.
The face is particularly vulnerable because facial skin is thinner than body skin, facial fat pads are discrete compartments rather than uniform layers, and the face is constantly visible, making even subtle changes noticeable.
Emerging Research
Choi and colleagues published a notable 2024 finding: semaglutide-induced weight loss actually improved mitochondrial energy efficiency in skeletal muscle.[6] This suggests that even when muscle size decreases, the remaining muscle tissue may function more efficiently. Whether this translates to preserved physical performance despite reduced mass requires longer-term human studies.
A separate line of research is investigating pharmaceutical approaches to the muscle loss problem. A 2025 Nature Communications study showed that blocking GDF8 (myostatin) and activin A in combination with GLP-1 drugs could prevent muscle loss while enhancing fat loss in obese mice and non-human primates. These approaches are not yet available clinically, but they point toward a future where the body composition trade-off may not be inevitable.
Argyrakopoulou and colleagues reviewed the full landscape of obesity pharmacotherapy effects on body composition in 2025, noting that this has become a central concern as GLP-1 drugs move from diabetes treatment into broader use for weight management.[7]
What the Evidence Does Not Yet Show
Several important gaps remain. No randomized controlled trial has specifically measured facial aging outcomes in GLP-1 users. The "ozempic face" literature consists primarily of clinical observations, case series, and expert commentary. The rate of facial volume loss relative to body fat loss has not been quantified. Whether slower titration schedules produce less visible skin changes is unstudied. Long-term outcomes beyond 2-3 years are unknown, including whether some skin remodeling occurs over longer time frames. And the interaction between GLP-1-mediated weight loss and existing skin conditions (rosacea, eczema, psoriasis) has not been systematically examined.
The Bottom Line
"Ozempic face" and "ozempic butt" are real phenomena driven by the rapid loss of subcutaneous fat and lean tissue on GLP-1 medications. Systematic reviews confirm that up to 40% of weight lost on semaglutide comes from lean mass, though the proportion varies widely between individuals and studies. Age, sex, protein intake, and physical activity levels all modulate the degree of lean mass loss and visible skin changes. The most effective mitigation strategies supported by current evidence are resistance training and adequate protein intake during treatment. Pharmaceutical approaches to decouple fat loss from muscle loss are in preclinical development but not yet available.